| 8.42 0.13 (1.57%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.61 |
1-year : | 12.4 |
| Resists | First : | 9.09 |
Second : | 10.61 |
| Pivot price | 8.38 |
|||
| Supports | First : | 8.1 |
Second : | 7.5 |
| MAs | MA(5) : | 8.34 |
MA(20) : | 8.4  |
| MA(100) : | 7.66 |
MA(250) : | 9.5 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.2 |
D(3) : | 56.8 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 14.96 | Low : | 6.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRMD ] has closed below upper band by 47.9%. Bollinger Bands are 39.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.54 - 8.6 | 8.6 - 8.64 |
| Low: | 8.03 - 8.09 | 8.09 - 8.14 |
| Close: | 8.34 - 8.44 | 8.44 - 8.51 |
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Mon, 13 Jul 2026
Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD - TradingView
Thu, 09 Jul 2026
Private Advisor Group LLC Buys 126,131 Shares of CorMedix Inc $CRMD - MarketBeat
Thu, 02 Jul 2026
CorMedix (Nasdaq: CRMD) expands Hurlburt role; Seckler leaves company - Stock Titan
Wed, 01 Jul 2026
CorMedix (NASDAQ: CRMD) replaces CBIZ with Ernst & Young as auditor - Stock Titan
Tue, 30 Jun 2026
Is CRMD Stock a Buy Now After Strong Growth and New Risks? - Yahoo Finance
Wed, 24 Jun 2026
CorMedix (CRMD) shareholders affirm directors but vote down multiple charter amendments - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 55 (%) |
| Shares Short | 14,930 (K) |
| Shares Short P.Month | 14,550 (K) |
| EPS | 2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | 45.2 % |
| Operating Margin | 49.9 % |
| Return on Assets (ttm) | 26.3 % |
| Return on Equity (ttm) | 65.5 % |
| Qtrly Rev. Growth | 226.1 % |
| Gross Profit (p.s.) | 4.68 |
| Sales Per Share | 5.09 |
| EBITDA (p.s.) | 2.91 |
| Qtrly Earnings Growth | 42.7 % |
| Operating Cash Flow | 198 (M) |
| Levered Free Cash Flow | 120 (M) |
| PE Ratio | 3.88 |
| PEG Ratio | 0 |
| Price to Book value | 1.51 |
| Price to Sales | 1.65 |
| Price to Cash Flow | 3.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|